OVER THE COUNTER PAIN MEDICATION MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In March 2024, The U.S. FDA has warned against using certain over-the-counter topical analgesics for pain relief before, during, or after cosmetic procedures like microdermabrasion, laser hair removal, tattooing, and piercing. The agency sent warning letters to six companies for illegal marketing of these products.
• In October 2023, the USFDA approval for the powerful non-opioid painkiller Maxigesic IV was announced by Belgium-based Hyloris Pharmaceuticals. Maxigesic IV is intended to be used as an adjuvant for moderate-to-severe pain and for mild-to-moderate pain, having been developed in collaboration with AFT Pharmaceuticals. An option to narcotic medications is provided by this postoperative infusion, which contains 1,000 mg of paracetamol and 300 mg of ibuprofen.
• In August 2022, Myovant Sciences, a biopharmaceutical company, and Pfizer announced that the USFDA had approved MYFEMBREE (relugolix, estradiol, and norethindrone acetate) as a once-daily pill for managing moderate to severe endometriosis pain in pre-menopausal women, with a treatment duration of up to 24 months. The approval, supported by data from Phase 3 trials and an open-label extension study, also includes treatment for heavy menstrual bleeding due to uterine fibroids.
• In June 2021, Bayer, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Astepro Allergy as an over-the-counter (OTC) product. It provides temporary relief from nasal congestion, runny nose, itchy nose, and other respiratory allergies.
• In March 2020, GSK received FDA approval for Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief. This marks the first FDA-approved OTC combination of ibuprofen and acetaminophen in the U.S., and it will be available globally.